chimeric antigen receptor FOXP3 T cells

Chimeric antigen receptor (CAR) FOXP3 T cells are an experimental cellular immunotherapy engineered to overcome the immunosuppressive barriers of the tumor microenvironment in solid tumors. These effector T cells are modified to express a CAR targeting the melanoma-associated antigen Tyrosinase-related protein 1 (TRP1) and to overexpress the transcription factor FOXP3. While FOXP3 is naturally a master regulator of regulatory T cells (Tregs), its ectopic expression in effector CAR-T cells is designed to enhance their metabolic fitness, promote persistence under conditions of nutrient deprivation or hypoxia, and protect the cells from activation-induced cell death (AICD). Developed by researchers at the Medical University of South Carolina, this approach has demonstrated the ability to delay tumor progression in preclinical melanoma models, particularly when total CAR-FOXP3-T cell populations are utilized in conjunction with supplemental CD4+ CAR-T cells.

Other names

CAR-FOXP3-T cellsCAR-FOXP-3-T cellsCAR-FOXP 3-T cellsFOXP3-expressing CAR-T cellsFOXP-3-expressing CAR-T cellsFOXP 3-expressing CAR-T cells